ESMO 2017 | Critical data points in the production of biosimilars

During the production of a biosimilar, there are certain data points which much be addressed to ensure its safety and efficacy. In this video, Richard Markus, MD, PhD, from Amgen, Los Angeles, CA, talks to us to discuss the three most important factors to consider, explaining their importance and how the study design used by Amgen addresses these points. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.